Counterfeit Immunotherapy Drugs in India: How to Protect Yourself
Counterfeit and illegally diverted immunotherapy vials have been reported in India, and the cases documented so far involve the most expensive checkpoint inhibitors on the market. In August 2026 Delhi Police announced 17 arrests over the alleged sale of counterfeit and diverted anti-cancer medicines to patients across six cities. This page sets out what the reported cases actually show, the warning signs a family can recognise without any technical knowledge, and the steps that make a vial verifiable. It is patient-safety reference content — not an allegation against any hospital, pharmacy, distributor or manufacturer.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
How big is the counterfeit cancer drug problem in India?
Nobody knows the true size, and any single percentage you are shown is an estimate. What is documented is a run of criminal cases. In August 2026 Delhi Police announced 17 arrests, including four staff of private hospitals, over counterfeit and illegally diverted anti-cancer medicines allegedly sold to patients across six Indian cities.
The detail in that case is what makes it worth understanding. Police described three alleged supply routes: diversion of stock from government institutions and warehouses, including medicines meant for CGHS beneficiaries; theft of vials and packaging material from private hospitals; and outright manufacture of counterfeit product. Officers said the accused imitated the vial and the packaging, used fake batch numbers, and filled vials with sterilised water before selling them at a discount. The recovery was put at 588 filled vials, six empty vials and seven empty boxes, with raids in Delhi and Navi Mumbai. Several of those arrested were based in Hyderabad.
Investigators also said original cartons were retained and reused for repackaging, and that batch numbers, MRP details and other identifying markings had been removed with chemicals such as acetone. That single detail tells a patient more than any statistic: the packaging in front of you can be genuine while the liquid in the vial is not.
This is not the first Indian case. A Delhi Crime Branch investigation was chargesheeted in July 2024, in which police alleged that antifungal medicine had been sold as costly oncology drugs. Reporting published by the International Consortium of Investigative Journalists in April 2026 noted that of nine Keytruda samples from that matter tested by the manufacturer's forensic laboratory, eight did not contain pembrolizumab. Those matters are before the courts, the accused deny wrongdoing, and nothing here should be read as a finding of guilt. The pattern is not confined to India: the World Health Organization has recorded dozens of product reports of falsified pembrolizumab worldwide since 2019, and has issued Medical Product Alerts on falsified oncology biologics including durvalumab in January 2025 and daratumumab in July 2026.
The products named above are genuine, approved medicines. The problem described here is criminal imitation and diversion of them. Nothing on this page suggests a defect in any manufacturer's product, and no comparison of quality between manufacturers is made or implied.
Did you know?
In the case announced in August 2026, police said the anti-cancer vials seized ranged from roughly Rs 15,000 to Rs 2 lakh each (reported figures, August 2026, indicative only). At that value a single stolen or refilled vial is worth more than most counterfeit consumer goods a criminal network could move in a month — which is precisely why oncology medicines have become a target, and why the discount that makes a vial affordable is also the thing that should stop you.
What are the warning signs of a counterfeit immunotherapy vial?
The strongest warning sign is the route, not the vial. A checkpoint inhibitor offered at a discount by anyone other than the treating hospital's pharmacy is the single clearest signal. Physical clues matter too, but a well-made counterfeit can look convincing, and a genuine carton can be refilled.
| Warning sign | Why it matters | What to do |
|---|---|---|
| A discount offered outside the hospital pharmacy | Reported cases have involved diverted or counterfeit stock sold below market price through intermediaries | Decline it, and tell the treating oncologist it was offered |
| No printed invoice, or an invoice with no batch number | Without an invoice there is no traceable supplier and no recall route if a batch is withdrawn | Refuse to accept the vial until a proper invoice is issued |
| Batch number, expiry or MRP smudged, scratched or removed | Police in the August 2026 case said identifying markings had been removed with chemicals to conceal origin | Do not use it — hand it to the hospital pharmacist |
| Carton seal opened, re-taped or missing | Genuine cartons have been emptied and refilled in reported cases; a broken seal removes the only tamper evidence | Quarantine the pack and ask for a replacement from stock |
| Batch number on the vial does not match the carton or the invoice | A mismatch means at least one of the three items did not travel with the others | Stop and escalate to the pharmacy before the infusion is prepared |
| Label misaligned, misspelt, or a different finish to previous cycles | Counterfeit packaging is imitated, and small inconsistencies are the usual tell | Compare against the previous cycle's pack and raise the difference |
| Vial arrives warm, or in a domestic cooler bag | Checkpoint inhibitors are refrigerated biologics; a broken cold chain cannot be seen in the vial | Treat it as unusable even if the pack looks perfect |
| Cash payment requested away from the billing counter | A transaction with no receipt is a transaction with no accountability | Pay only at the hospital billing counter, and keep the receipt |
Case details cited above are from police statements reported in the Indian press in August 2026 and from published investigative reporting in April 2026. The matters are allegations pending before the courts.
How do you verify an immunotherapy vial is genuine?
You verify the paper trail and the cold chain, not the liquid. No patient can test a vial at the bedside, and no visual check is conclusive. What a family can do is insist the vial reached them through a route that can be traced backwards to the manufacturer, and refuse any vial that cannot.
- Source it through the treating hospital's own pharmacy. From the manufacturer or an authorised distributor, on the hospital's account. A vial bought around the hospital cannot be verified afterwards by anyone.
- Insist on a printed invoice. It should name the product, batch number, expiry date, supplier and drug licence number. Keep it — it is the paper trail if a batch is ever recalled.
- Match vial, carton and invoice. Batch number and expiry should agree across all three, and the carton seal should be intact when it reaches the day-care unit.
- Scan the bar code or QR code where one is present. It is a useful cross-check, not proof on its own — see the section below on what the code cannot do.
- Confirm an unbroken cold chain at 2 to 8 degrees Celsius. A vial carried home, left out, or frozen is unsafe even when it is entirely genuine.
- Photograph the vial, carton and invoice before the infusion. It takes ten seconds, and it is the only evidence that exists if a question arises months later.
Our companion page on how to verify an immunotherapy vial is genuine walks through each check in detail, including what to inspect on the carton and what to ask the pharmacy to document.
Who these medicines are not for — and what this page is not
Most people with cancer in India are not candidates for a checkpoint inhibitor at all, and a cheaper vial does not widen who it suits. These medicines are approved for a defined set of cancers, and within those, eligibility usually turns on stage, on what treatment came before, and in some cancers on a biomarker result. A patient who is not eligible gains nothing from a genuine vial and is exposed to real harm by a counterfeit one.
They are also not suitable, without specialist assessment, for people with active or uncontrolled autoimmune disease, people taking high-dose immunosuppressive medicines, or organ transplant recipients. Checkpoint inhibitors work by lifting a brake on the immune system, which is exactly why those situations need individual review by an oncologist rather than a general rule from a web page.
This page has its own limits. It is not a sourcing guide, and it does not tell anyone where to obtain a vial. It is not an allegation against any named hospital, pharmacy, distributor, manufacturer or individual — the matters described are police allegations pending before the courts. It makes no comparison of quality between manufacturers. It is not a price list, and no figure here is a CION rate for any named product. And it is not a substitute for reporting a suspect vial to the regulator, which is the only step that protects the next patient as well as this one.
Why is the counterfeit market growing alongside cheaper immunotherapy?
Because a large, visible price gap creates a market for anything that looks like the cheaper option. Immunotherapy in India has been out of reach for most families for a decade. Prices are now moving, unevenly, and a counterfeit trade has grown in the same space — offering the discount without the medicine.
Two real price stories sit behind this. A domestic nivolumab biosimilar launched in India on 22 January 2026 at manufacturer-announced prices of roughly a quarter of the reference brand. Pembrolizumab is on a different clock — its protection is expected to begin lapsing around 2028-29, so no equivalent price fall should be assumed for that molecule in India yet. Both figures come from published announcements and reporting, and both are indicative only, as of August 2026.
The consequence for families is uncomfortable but simple. A genuine discount now exists for one molecule, which makes an offered discount sound plausible for every molecule, and counterfeiters rely on exactly that plausibility. Our page on which immunotherapy medicines have Indian biosimilars today sets out where a legitimate lower price exists and where it does not — the fastest way to tell a real saving from a trap.
Funding patterns add to the risk. Much of this treatment is paid out of pocket, often with money sent by a relative abroad, and a family member under pressure to reduce a bill is a natural target for an intermediary promising the same drug for less. Buying immunotherapy medicines outside the hospital covers the rules and the risks of that route in detail.
Will the QR code on the pack prove a vial is real?
It will help, and it is not yet in force for most anti-cancer packs. On 25 June 2026 the Union Health Ministry notified an amendment to the Drugs Rules, 1945 bringing all anti-cancer drugs — along with vaccines, antimicrobials and NDPS-scheduled drugs — under Schedule H2, the bar code and QR code track-and-trace framework.
The code has to carry nine data elements: a unique product identification code, the proper and generic name of the drug, the brand name, the name and address of the manufacturer, the batch number, the date of manufacture, the date of expiry, the manufacturing licence number, and details of excipients. Until this amendment, the requirement applied only to the top 300 pharmaceutical brands in the country.
The timing matters for anyone in treatment now. For anti-cancer medicines the requirement comes into force from 1 July 2027, with manufacturers encouraged to adopt it voluntarily before then. So through 2026 and much of 2027, a missing code on an anti-cancer pack is not by itself evidence of anything.
And there is a limit that will still apply after 2027. In the cases reported so far, some counterfeit product was placed in genuine cartons that had been emptied, retained and reused. A code printed on a real carton will scan correctly regardless of what is inside it. The code strengthens the audit trail across the supply chain; it does not replace the invoice, the intact seal, the batch match or the cold chain.
What should you do if you think a vial was counterfeit?
Preserve everything, tell the treating oncologist, then report it. The instinct is to throw the pack away or say nothing because nothing can be proved. Both make things worse. Batches are traced from exactly this kind of report, and one family's report is often what identifies a wider problem.
- Keep the vial, carton, outer packaging, invoice and payment record. Photograph all of them, including the batch number and expiry, before anything is handed over.
- Tell the treating oncologist the same day. An unexplained lack of response, or an unusual reaction, is clinically relevant information and may change what happens next.
- Ask the hospital pharmacy to quarantine the rest of that batch. A responsible pharmacy will isolate the stock and check its own procurement records rather than wait.
- Report it to the state Drugs Control Administration. In Telangana that is the state drugs regulator, which investigates spurious and substandard medicines and has acted on anti-cancer drug cases.
- Report it to CDSCO. The Central Drugs Standard Control Organisation maintains a public route for reporting spurious drugs at cdsco.gov.in.
- Lodge a police complaint if money changed hands outside the hospital. Selling spurious drugs is a criminal offence under the Drugs and Cosmetics Act, 1940, not merely a consumer dispute.
- Report even when you are not sure. Regulators expect uncertain reports. Waiting for certainty is how a batch stays in circulation.
Reading further on authenticity, price and access
- How to Verify an Immunotherapy Vial Is Genuine — the checks above, step by step, including what to ask the hospital pharmacy to document.
- Buying Immunotherapy Medicines Outside the Hospital: Risks and Rules — what the law allows, what it does not, and why the discount exists.
- Which Immunotherapy Medicines Have Indian Biosimilars Today? — where a legitimate lower price genuinely exists, molecule by molecule.
- Immunotherapy Medicines Explained — the full reference section this page sits in, including how pricing and regulatory information is sourced.
- Immunotherapy at CION — the pillar guide to what immunotherapy is, who it suits, and how it is delivered as day care.
Where the facts on this page come from
- Ministry of Health and Family Welfare / PIB, 25 June 2026 — Schedule H2 QR-code traceability extended to all anti-cancer drugs, in force 1 July 2027. Press release.
- Central Drugs Standard Control Organisation — consumer information and the reporting route for spurious drugs.
- World Health Organization — Medical Product Alerts on falsified medical products, including oncology biologics.
- Published reporting, April and August 2026 — Delhi Police statements on the arrests, recoveries, alleged supply routes and reported per-vial price range; and investigative reporting on falsified pembrolizumab and forensic testing of samples from the earlier Delhi case.
This page is editorial reference content on medicine authenticity. It is not an offer, a price list, or a recommendation to use any named product. Every figure quoted is from a published official announcement or published reporting, named and dated, indicative only as of August 2026, and none is a CION rate for any named molecule. Criminal matters referred to are allegations pending before the courts, and no individual, hospital, pharmacy or company is accused here of wrongdoing. No comparative quality claim is made between manufacturers. Whether any immunotherapy medicine has a role in a particular patient's treatment is a decision for the treating oncologist.